Salk Institute

Technologies Available for Licensing

Treatment of Liposarcomas Using a Combination of Thiazolidinediones and Retinoid X Receptor Selective Agonists

Inventors: Ron Evans, Peter Tontonoz, and Barry Forman
Potential Uses: Oncology, Drug Discovery and Development
Compositions useful for the treatment of liposarcomas

Liposarcoma is the most common soft tissue malignancy in adults, accounting for at least 20% of all sarcomas in this age group. Localized disease is treated primarily with surgery, often in combination with radiotherapy. Metastatic liposarcoma is associated with an extremely poor prognosis, with average five year survival ranging from 70% to 25%, depending on the type of tumor. The development of effective, noninvasive methods for treating liposarcomas would represent a significant advancement in the therapeutic arts. It has been discovered that PPAR-gamma is expressed consistently in each of the major histologic types of human liposarcoma. Maximal activation of PPAR-gamma with exogenous ligand (a thiazolidinedione or derivative thereof) promotes terminal differentiation of primary human liposarcoma cells, thereby blocking further proliferation. It has also been discovered that RXR-specific ligands are potent adipogenic agents in cells expressing the PPAR-gamma/RXR-alpha heterodimer and that simultaneous treatment of liposarcoma cells with a thiazolidinedionyl moiety (a PPAR-gamma-selective class of compounds) and an RXR-specific ligand results in an additive stimulation of differentiation. The invention includes compositions useful for the treatment of liposarcomas.

Salk No: S96023A
Patent Status: U.S. Patent No. 6,586,455 issued July 1, 2003
Publications: PNAS USA 1997 Jan 7; 94(1):237-41
License Terms: Exclusive or Nonexclusive licenses available
Contact: Michelle Booden, Ph.D., Director of Licensing, 858.453.4100 x1612,

Get Involved

Sign up for our email newsletter

Fill out my online form.
Salk Institute for Biological Studies
Street: 10010 N Torrey Pines Rd
City: La Jolla, CA 92037
Phone: 858.453.4100
Charity Navigator Rating
  • Salk Twitter
  • Salk LinkedIn
  • Salk Facebook
  • Salk Instagram
  • Salk Google+
  • Salk YouTube
  • Salk RSS Feed
© Copyright 2015 Salk Institute for Biological Studies | Privacy Policy About Scientists & Research News & Media Events Support